Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.00%, a 9.09% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.40%, a 1.38% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.34%, a 1.40% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.28%, a 77.59% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 6.38% decline from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.70%, a 5.62% decline from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.98%, a 15.55% increase from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.31%, a 212.32% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-10 | |||||
| 2026-03-31 | 4.00% 10-Q · filed 2026-05-11 | |||||
| 2025-12-31 | 4.40% 10-K · filed 2026-03-03 | |||||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | 4.40% 10-Q · filed 2026-08-10 | |||||
| 2025-03-31 | 4.40% 10-Q · filed 2026-05-11 | |||||
| 2024-12-31 | 4.70% 10-K · filed 2026-03-03 | |||||
| 2024-09-30 | 4.70% 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | 4.70% 10-Q · filed 2025-08-11 | |||||
| 2024-03-31 | 4.34% 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | 4.98% 10-K · filed 2026-03-03 | |||||
| 2023-09-30 | 4.60% 10-Q · filed 2024-11-08 | 4.63% 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | 4.30% 10-Q · filed 2024-08-08 | 4.28% 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | 4.28% 10-Q · filed 2024-05-08 | |||||
| 2022-12-31 | 4.31% 10-K · filed 2025-03-17 | |||||
| 2022-09-30 | 3.94% 10-Q · filed 2023-11-08 | |||||
| 2022-06-30 | 3.36% 10-Q · filed 2023-08-03 | |||||
| 2022-03-31 | 2.41% 10-Q · filed 2023-05-08 | |||||
| 2021-12-31 | 1.38% 10-K · filed 2024-02-29 | |||||
| 2021-09-30 | 1.15% 10-Q · filed 2022-11-02 | |||||
| 2021-06-30 | 1.14% 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | 1.11% 10-Q · filed 2022-05-10 | |||||
| 2020-12-31 | 1.51% 10-K · filed 2023-03-16 | |||||
| 2020-09-30 | 1.51% 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | 1.51% 10-Q · filed 2021-08-04 | |||||
| 2020-03-31 | 1.51% 10-Q · filed 2021-05-05 | |||||
| 2019-12-31 | 2.62% 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |